Selpercatinib RAI Thyroid (RAISE Trial)

Selpercatinib RAI Thyroid (RAISE Trial)

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description
This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and RET fusion. The study involves taking a study drug called selpercatinib for approximately 6 months prior to receiving radioiodine therapy (RAI). The overall goal of this study is to find out if taking the study drug before RAI works better than receiving RAI alone (the usual standard of care treatment). 

Eligibility and criteria
IRB Number:
23-021524
Eligible age range:
2 years - 21 years
Clinical trial phase:
Phase II
Official title:
Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults with Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions (RAISE Trial)

What to expect
As a participant in the research, you will:
  • Receive a study drug called Selpercatinib
  • Complete frequent clinic visits at CHOP
  • You may need to delay your standard of care RAI therapy
  • Have periodic imaging performed to evaluate your response to treatment
If you agree to participate in the optional imaging sub-study, you will:
  • Have an extra Whole Body Scan (WBS)
  • Consume a low iodine diet for 7-14 days before the WBS scan
  • Receive a drug called Thyrogen and receive a low dose of radioactive sodium iodine before the WBS scan

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.